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Background: Patients with chronic kidney disease are at increased risk of cystic kidney disease that requires imaging
monitoring in many cases. However, these same patients often have contraindications to contrast-enhanced computed
tomography and magnetic resonance imaging. This study evaluates the accuracy of contrast-enhanced ultrasound
(CEUS), which is safe for patients with chronic kidney disease, for the characterization of kidney lesions in patients with
and without chronic kidney disease.
Methods: We performed CEUS on 44 patients, both with and without chronic kidney disease, with indeterminate or
suspicious kidney lesions (both cystic and solid). Two masked radiologists categorized lesions using CEUS
images according to contrast-enhanced ultrasound adapted criteria. CEUS designation was compared to
histology or follow-up imaging in cases without available tissue in all patients and the subset with chronic
kidney disease to determine sensitivity, specificity and overall accuracy.
Results: Across all patients, CEUS had a sensitivity of 96% (95% CI: 84%, 99%) and specificity of 50% (95% CI: 32%, 68%)
for detecting malignancy. Among patients with chronic kidney disease, CEUS sensitivity was 90% (95% CI: 56%, 98%),
and specificity was 55% (95% CI: 36%, 73%).
Conclusions: CEUS has high sensitivity for identifying malignancy of kidney lesions. However, because specificity
is low, modifications to the classification scheme for contrast-enhanced ultrasound could be considered as a way
to improve contrast-enhanced ultrasound specificity and thus overall performance. Due to its sensitivity, among
patients with chronic kidney disease or other contrast contraindications, CEUS has potential as an imaging test to
rule out malignancy.
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The incidence of kidney cancer is increasing with over
60,000 new kidney cancer diagnoses projected for 2017.
Kidney cancer is also deadly. Over 14,000 associated
deaths are expected in 2017 [1]. If detected early, kidney
cancer can be treated effectively with surgery alone.
Benign cystic lesions are common, accounting for up to
30% of all identified lesions [2]. Distinguishing malignant
kidney neoplasms from benign lesions is crucial to deter-
mining appropriate treatment. Diagnostic options in-
clude biopsy [3, 4] or interval imaging over months or
years [5–7]. Cystic lesions can be characterized with
contrast-enhanced computed tomography (CT) or mag-
netic resonance (MR) imaging [8] using the Bosniak
criteria [9, 10].
However, Bosniak classification requires contrast en-
hancement which may pose risk in some patients with
compromised kidney function. Risks associated with
iodinated contrast agents used with CT imaging include
further impairment in kidney function for those with
advanced stages of chronic kidney disease (CKD). Use of
gadolinium-based contrast agents in this population also
poses a rare but serious risk of nephrogenic sclerosing
fibrosis. Incidence of this disease has virtually disappeared
with more stringent screening prior to gadolinium expos-
ure and use of agents with better risk profiles. However,
gadolinium deposition in various organs is now being pos-
tulated even in patients with normal kidney function,
although the clinical significance is not yet known [11, 12].
Patients with impaired kidney function experience pro-
longed exposure to gadolinium since it is cleared primarily
by the kidneys and thus have an increased risk of gadolin-
ium deposition [13]. Over 40 million people in the United
States have chronic kidney disease (CKD), and this popula-
tion is rapidly growing (USRDS 2016). These patients have
substantially increased risk for the development of kidney
cancer [14–16]. However, the typical screening tools of
contrast-enhanced CT and MR are often contraindicated
in patients with advanced stages of CKD. In patients with
moderate stages of CKD, kidney-protective measures can
be taken but add additional steps, can be cumbersome and
do not entirely eliminate risk. Even in these populations, if
a patient has a high-risk lesion, the benefits of a contrast
CT or MR study may outweigh the risks from contrast
exposure. For patients with lower or moderate risk lesions,
the risk of contrast-enhanced CT or MR may not be worth
the benefit. Radiologic options for this population are
limited [17]. Non-contrasted surveillance imaging is often
performed, but this is inferior to contrast enhanced studies
for lesion characterization.
A potential alternative imaging modality for evaluating
kidney lesions is contrast-enhanced ultrasound (CEUS).
CEUS has been used to characterize indeterminate lesions
in multiple organs [18, 19], including the kidneys [20–27].CEUS has the ability to detect vascularization as the
microbubble contrast agent remains purely intravascular
[28, 29]. A unique aspect of CEUS is its ability to image
contrast dynamics in real time [30, 31]. US contrast agents
have a low serious adverse event rate of 0.006–0.009%,
consisting primarily of anaphylactoid reactions that
resolve when the contrast is cleared and typically do
not necessitate hospitalization [32, 33]. Less serious
side effects that are also rare and typically transient,
resolving when the contrast agent is cleared, include
headache, dizziness, flushing, nausea, flank pain and
chest pain. An additional benefit setting them apart
from other contrast agents is that they are excreted
by exhalation through the lungs and are therefore not
nephrotoxic and safe for patients with kidney disease.
Despite the potential for CEUS as a diagnostic option
among individuals with CKD, few studies have evaluated
CEUS in this population, although interest is increasing
[34, 35]. In this exploratory pilot study, we sought to in-
vestigate the diagnostic accuracy of CEUS for detecting
enhancement of kidney lesions, and thus risk of malig-
nancy, in populations with and without CKD and subse-
quently determine if this imaging modality has potential
to be an alternative screening tool in patients with contra-
indications to contrast CT or MR. We hypothesized that
CEUS has sensitivity comparable to contrast-enhanced
CT or MR among individuals with and without CKD.Methods
Study design and participants
We performed a prospective imaging study of CEUS in
patients with kidney lesions identified by prior imaging
(ultrasound, CT or MR) obtained as part of routine clin-
ical care. This study was performed in compliance with
the policies related to the use of human subjects of the
Biomedical Institutional Review Board. All procedures
performed were in accordance with the ethical standards
of the institutional research committee and with the
1964 Helsinki declaration and its later amendments or
comparable ethical standards. Informed consent was
obtained from all individual participants included in the
study. This pilot study was designed to generate needed
data to allow for accurate power calculations in future
studies. The numbers of true positives and true negatives
were random and not fixed by the study design. The
total sample size of 48 was chosen based on based on
estimated ability to recruit 2–3 patients a month over a
2-year time period. Any patient meeting inclusion/exclu-
sion criteria was offered participation in the study. Inclu-
sion criteria were: 1) eligibility for nephrectomy or
ablative therapy based on identification of a kidney lesion
on prior imaging, or having CKD and an incompletely
characterized kidney lesion on prior imaging; and 2) the
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protocol requirements.
Exclusion criteria included: 1) active cardiac disease, in-
cluding class IV congestive heart failure, unstable angina,
severe arrhythmia, myocardial infarction within 14 days
prior to the study and uncontrolled blood pressure (>150/
90 mmHg); 2) severe pulmonary hypertension or adult re-
spiratory distress syndrome; 3) hypersensitivity to the
Definity (Perflutren lipid) US contrast agent; 4) critical ill-
ness or intensive care unit status; 5) right-to-left cardiac
shunt; 6) unstable neurologic disease within 3 months; 7)
invasive kidney procedure between time of lesion identifi-
cation and CEUS; 8) mental illness or drug abuse; and 9)
pregnancy or lactation. Patients were recruited from Ur-
ology and Nephrology clinics from July 2013 to November
2014. After obtaining informed written consent, patients
underwent CEUS per a standard study protocol with low
mechanical index (MI) (0.19) imaging.
Because the Bosniak criteria [9, 10] were not designed
for ultrasound, for cystic lesions, we applied an adapted
Bosniak criteria to CEUS, including both B-mode and
CEUS images, (Additional file 1: Table S1) by substitut-
ing “internal echogenicity” within a cyst for “high-at-
tenuation”. High attenuation within a cyst is an indicator
of proteinaceous or hemorrhagic content, which appears
on US as internal echogenicity. Lesions were categorized
as solid or Bosniak I-IV by CEUS. In primary analyses,
the CEUS diagnosis was compared to the reference
standard of tissue diagnosis (malignant/benign). CEUS
Bosniak I, II and IIF lesions were considered negative
since these are generally managed non-surgically; CEUS
Bosniak III, IV and solid lesions were considered positive
since these are generally managed surgically. In second-
ary analyses, we used a reference standard of tissue diag-
nosis or follow-up imaging (obtained 12–26 months
after CEUS). The follow-up interval and imaging modal-
ity was determined by the individual’s doctor. Follow-up
imaging modalities included standard B-mode US, con-
trast CT and contrast MR. For patients with more than
one follow-up imaging examination, the last available
examination was used for analysis. Stable lesions were
considered negative. A worsening of concerning lesion
characteristics (septations, calcifications, mural thick-
ness, irregularity or nodules) was considered positive.
The reference standard of follow-up imaging was used
because tissue diagnosis was not feasible in many
patients given the risks associated with surgery and
biopsy.
In separate analyses among patients who had a clin-
ical contrast-enhanced CT or MR (n = 25), CEUS
Bosniak classification was compared to CT/MR Bosniak
classification, by the same blinded readers, to determine
inter-modality agreement. To determine inter-reader
agreement, answers to lesion characteristic questions(Additional file 1: Table S1) were compared across readers
for CEUS and CT/MR studies. The median time interval
between CEUS and CT/MR was 29 days (interquartile
range: 20–44).
Imaging procedure and analysis
CEUS was performed with the Siemens Acuson Sequoia
512 (Siemens, Mountain View, CA, USA) with contrast
specific software using a 4C1 abdominal transducer. A
standard MI of 1.9 was used for B-mode imaging and a
low MI of 0.19 was used for all CEUS clips. The MI is a
metric used to describe potential bioeffects caused by
ultrasound, specifically cavitation bioeffects. A higher
MI indicates increased likelihood of bioeffects. Typical
B-mode ultrasound imaging uses an MI of 1.9. Low MI
(0.19) is used in CEUS to avoid disruption of microbub-
bles. Scanning was performed by registered sonogra-
phers trained in contrast imaging. Lesions were located
with B-mode ultrasound. For patients with multiple
lesions, the most complex lesion as designated on prior
imaging was chosen for CEUS imaging. The transducer
was then positioned over the lesion so that the imaging
plane included part of the normal kidney parenchyma.
The contrast agent, Perflutren Lipid microspheres
(DefinityR, Lantheus, North Billerica, MA), was pre-
pared as a bolus injection, as described in the package in-
sert instructions. The total contrast volume administered
was based on weight, 0.50 mL for <125 lb., 0.65 mL for
125–185 lb., and 1.0 mL for >185 lb. This contrast was di-
luted in saline to a final volume of 5 mL and injected over
15 s, followed by a 5 mL saline flush. Lesions were imaged
for 3 min after contrast injection.
Images were de-identified and interpreted by two radiol-
ogists blinded to lesion diagnosis and to each other’s
reads. A custom graphical user interface (GUI) developed
in MATLAB (MathWorks, Natick, MA) displayed de-
identified CEUS and B-mode clips accompanied by ques-
tions related to lesion characteristics (Additional file 2:
Figure S1). Two abdominal radiologists (identified as
Reader 1 and Reader 2 with 20 and 15 years’ experience in
ultrasound imaging, respectively) not involved in image
acquisition independently performed the blinded study
reads. Both readers participated in a preliminary training
session and performed CEUS radiology literature review,
particularly from experienced centers such as the Univer-
sity of Calgary, and international ultrasound societies [36].
Readers used both B-mode and CEUS images to answer
lesion characteristic questions, classify the lesions as solid
or cystic, and if cystic, apply the adapted Bosniak criteria
(Additional file 1: Table S1). CEUS enhancement was
determined by the subjective determination of the ap-
pearance of contrast on the image. The diagnosis
based on the B-mode and CEUS images is designated
“CEUS diagnosis”. The same radiologists reviewed the
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able and answered the same questions. A 3-month delay
between CEUS and CT/ MR readings was instituted to
prevent recall.
Contrast-enhanced CTs were acquired with a 16- to
64-slice MDCT scanner. A non-contrasted scan was first
obtained. 100 mL of Iohexol 755 mg/ml (Omnipaque
350 – GE Healthcare, Milwaukee, WI) was administered
intravenously at 3-4 mL/s. MRs were performed on 1.5
Avanto and 3 T Trio (Siemens, Iselin, NJ, USA). 10 ml
of Gadobenate Diglumine (Multihance, Bracco Diagnos-
tics, Monroe Township, NJ) was administered intraven-
ously. For details about the CEUS, CT and MR imaging
techniques, see Additional file 3.
Statistical analysis
For the primary analysis, CEUS diagnosis was compared
to the reference standard of tissue diagnosis. For second-
ary analyses, CEUS diagnosis was compared to tissue
diagnosis or follow-up imaging diagnosis. Sensitivity, spe-
cificity and overall accuracy (number of CEUS correct
diagnoses/total number of lesions) were calculated for
each reader separately, with 95% confidence intervals
using the exact Pearson-Clopper method. Reader data
were considered separately and combined, with measures
calculated using generalized estimating equations [37],
along with asymptotic 95% confidence intervals under a
working independence assumption between readers.
Performance measures (sensitivity, specificity and
overall accuracy) were also determined for the subset of
patients with CKD, with analyses analogous to those
used in the full cohort. These exploratory secondary
analyses were stratified according to CKD severity:
early CKD (GFR ≥ 30 mL/min) and advanced CKD
(GFR < 30 mL/min, including patients on dialysis or
the native kidney of a patient with a kidney transplant).
Because of small sample sizes, the current study was
underpowered to demonstrate statistically significant dif-
ferences in diagnostic accuracy between late and early
CKD groups. To detect the observed differences in total
accuracy of 0.8 versus 0.5 at significance level 0.05 using a
2-sided test of two proportions, 40 subjects in each CKD
group would be needed for 80% power and 50 subjects
per group for 90% power.
Additional exploratory subgroup secondary analyses con-
sidered accuracy across patients with a priori-designated
co-morbid conditions (hypertension, diabetes mellitus,
cardiovascular disease and obesity) and across lesion
sizes (<3 vs. ≥3 cm). Fisher’s exact test was used to
calculate statistical significance. Agreement between
readers was calculated using sample proportions. All
analyses were conducted in SAS version 9.4 (Cary,
NC). Two-tailed p-values of <0.05 were used to indi-
cate statistical significance.Results
Patient and lesion characteristics
A flowchart of patient recruitment is shown in Fig. 1. Of
the 48 patients who underwent CEUS examination, 2
were excluded due to poor technical quality. Of the 46
patients that received CEUS classification, 2 were
excluded due to lack of follow-up. One died of unrelated
cause (meningitis), and another patient with a suspicious
lesion recommended for nephrectomy opted for surveil-
lance, but was lost to follow-up. A total of 44 patients
had interpretable CEUS imaging with one lesion exam-
ined per patient and either tissue diagnosis or follow-up
imaging results available. A summary of patient and
lesion characteristics is displayed in Table 1. Mean pa-
tient age was 56, with 70% (31/44) being male. The most
common co-morbidities were hypertension (68%, 30/44),
hyperlipidemia (50%, 22/44) and obesity (50%, 22/44).
Of the 44 patients, 25 had CKD, including 7 patients
receiving dialysis and 3 who had received a kidney trans-
plant. All 3 had functioning transplants. Patients with
CKD were more likely to be older and have hypertension
and cardiovascular disease.
The most common initial study for patients without
CKD was contrast CT (n = 15) followed by contrast MR
(n = 5). The most common initial study for patients with
CKD was a conventional, non-contrasted ultrasound
(n = 17), followed by non-contrasted CT (n = 8). Patients
with CKD were more likely to have bilateral lesions with
smaller diameters of individual lesions. The average diam-
eter based on initial imaging study was 3.51 cm in non-
CKD patients and 3.09 cm in CKD patients.
Of the 44 patients in the study cohort (Fig. 1), 23 under-
went surgery/biopsy and 21 were followed with serial
imaging. Of the 23 surgical patients, 22 had nephrectomy
and 1 had fine needle aspiration showing angiomyoli-
poma. The primary reference standard of histologic diag-
nosis categorized 2 lesions as benign and 21 as malignant.
The observed malignancy subtypes (clear cell, papillary,
and chromophobe) followed patterns observed in prior
studies [38]. More papillary renal cell carcinomas were
observed in patients with CKD compared to patients with-
out CKD, as has been previously observed [39]. The
secondary reference standard of tissue diagnosis or
diagnosis on follow-up imaging categorized 21 lesions
as benign (2 by histology and 19 by imaging) and 23
as malignant (21 by histology and 2 by imaging). The
mean follow-up period was 20 months and ranged
from 12 to 26 months.
CEUS accuracy
Accuracy was defined as the number of CEUS correct
diagnoses/total number of lesions. Table 2 displays com-
bined and individual reader accuracy results, including
sensitivity, specificity and overall accuracy for the
Fig. 1 Patient flowchart. Flowchart of patient recruitment, exclusions and numbers for final analysis
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tissue diagnosis as the reference standard, combined
overall accuracy was 87% (95% CI: 69%, 95%). In second-
ary analyses using tissue or follow-up imaging as the
reference standard, combined overall accuracy was 73%
(95% CI: 59%, 83%). The cohort size was inadequate for
analyzing CEUS characterization based on histological
subtype (clear cell, papillary, or chromophobe).Inter-reader agreement
CEUS inter-reader agreement results are shown in Fig. 2.
The highest rate of agreement was seen with calcifications
(89%), overall malignant/benign designation (87%), mural
nodules (83%) and lesion enhancement (80%). The lowest
rate of agreement was with Bosniak class (57%), septa
(63%) and rim enhancement (65%). Low rate of Bosniak
class agreement was not surprising as there are 6 possible
categories (solid, I, II, IIF, III and IV).CEUS diagnoses compared to contrast CT/MR diagnoses
CEUS diagnosis was compared to CT/MR diagnosis for
25 patients who had both CEUS and a contrasted CT/
MR. Of the studies that were positive (Bosniak III, IV or
solid) by CT/MR, 89% were also positive by CEUS for
reader 1 and 96% for reader 2 (Table 3). Of the studies
that were negative (Bosniak I, II and IIF) by CT/MR,
83% were read as positive by CEUS for reader 1 and
100% for reader 2. There was no overlap in confidence
intervals for these two groups for either reader. Overall
agreement between CT/MR and CEUS diagnoses was
72% for reader 1 and 92% for reader 2. Inter-reader
agreement with CT/MR was found to be 81% for malig-
nant/benign designation.Accuracy in patients with chronic kidney disease
Of the 25 patients with CKD, 5 (20%) had tissue diagno-
ses. All 5 of these patients had malignant lesions, and
Table 1 Patient and lesion characteristics
Total (N = 44) (+) CKD (n = 25) (−) CKD (n = 19)
Age (years)
Mean ± S.D. 56 ± 14 59 ± 13 51 ± 14
Male 31 (70%) 18 (72%) 13 (68%)
Co-morbid conditions
Hypertension 30 (68%) 20 (80%) 10 (53%)
Diabetes 10 (23%) 5 (20%) 5 (26%)
Hyperlipidemia 22 (50%) 13 (52%) 9 (47%)
Cardiovascular disease 9 (20%) 8 (32%) 1 (5%)
History of renal cell carcinoma 3 (7%) 2 (8%) 1 (5%)
Obesitya 22 (50%) 11 (44%) 11 (58%)
Initial Studyb
Non-contrast CT 11 (25%) 8 (32%) 3 (16%)
Contrast CT 20 (45%) 5 (20%) 15 (79%)
Non-contrast MR 1 (2%) 0 1 (5%)
Contrast MR 6 (14%) 1 (4%) 5 (26%)
Conventional US 17 (39%) 17 (68%) 0
Laterality of lesion
Right 19 (43%) 12 (48%) 7 (37%)
Left 20 (45%) 9 (36%) 11 (58%)
Bilateral 5 (11%) 4 (16%) 1 (5%)
Laterality of imaging
Right 21 (48%) 14 (56%) 7 (37%)
Left 23 (52%) 11 (44%) 12 (63%)
Diameter by imaging (cm)c
Mean (range) 3.27 (1.4–7.9) 3.09 (1.4–7.9) 3.51 (1.4–6.6)
Diameter by histology (cm)d
Mean (range) 3.39 (0.4–7)
(n = 20)
2.88 (0.4–5.6)
(n = 4)
3.51 (1.2–7)
(n = 16)
Diagnosis
Clear cell RCC 14 (32%) 1 (4%) 13 (68%)
Papillary RCC 5 (11%) 3 (12%) 2 (11%)
Chromophobe RCC 2 (4%) 1 (4%) 1 (5%)
Angiomyolipoma 1 (2%) 0 1 (5%)
Oncocytoma 1 (2%) 0 1 (5%)
Surveillance 21 (48%) 20 (80%) 1 (5%)
Stable/benign 19 19 0
Progressed/malignant 2 1 1
CKD stage
Non-CKD 19 (43%) 0 19 (100%)
CKD II 2 (4%) 2 (8%) 0
CKD III 9 (20%) 9 (36%) 0
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Table 1 Patient and lesion characteristics (Continued)
CKD IV 4 (9%) 4 (16%) 0
CKD V on dialysis 7 (16%) 7 (28%) 0
Transplant 3 (7%) 3 (12%) 0
Probable cause of CKD
Hypertensive Nephrosclerosis 11 (44%)
Diabetic Kidney Disease 4 (16%)
Hypertension/Diabetic Kidney Disease 1 (4%)
Polycystic Kidney Disease 2 (8%)
Chronic Interstitial Nephritis 2 (8%)
Membranous Nephropathy 1 (4%)
Focal Segmental Glomerulosclerosis 1 (4%)
Medullary Sponge Kidney 1 (4%)
NSAID-induced Nephropathy 1 (4%)
Lithium Nephrotoxicity 1 (4%)
CKD chronic kidney disease, CT computed tomography, MR magnetic resonance imaging, US ultrasound, RCC renal cell carcinoma
aDefined as BMI ≥ 30
bPercentages add to greater than 100% as 11 patients had multiple studies prior to CEUS
cBy largest dimension
dOne sample was resected in multiple pieces with no histologic diameter available
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56%, 98%). Compared to tissue or follow-up diagnosis,
sensitivity was 90% (95% CI: 56%, 98%) and specificity
55% (95% CI: 36%, 73%). Overall accuracy was 62% (95%
CI: 44%, 77%). Further analysis by CKD stage showed
CEUS sensitivity, specificity and overall accuracy was
lower in patients with advanced (stage IV, V, dialysis and
transplant) versus early (stage II and III) CKD. The com-
bined overall accuracy for early CKD was 77% (95% CI:
48%, 93%), and 50% (95% CI: 29%, 71%) for advanced
CKD. Sensitivity and specificity and individual accuracies
for each reader are presented in Table 4.
Numbers were not sufficient to detect significant
differences in accuracy between patients with and
without hypertension, diabetes, cardiovascular diseaseTable 2 Accuracy of CEUS compared to tissue diagnosis (primary
(secondary analysis)a
Reader 1
Tissue diagnosis
(N = 23)
Tissue or follow-up
imaging
(N = 44)
Tissue d
(N = 23)
Sensitivity 90%
(78%, 100%)
[19/21]
91%
(80%, 100%)
[20/22]
100
(100%,
[21/
Specificity 0%
(0%, 0%)
[0/2]
59%
(39%, 80%)
[13/22]
0%
(0%,
[0/
Overall Accuracy 83%
(67%, 98%)
[19/23]
75%
(62%, 88%)
[33/44]
91
(80%, 1
[21/
aResults presented as accuracy metrics (95% CI) and [positive or negative reads/tota
considered per reader and as a combination of the 2 readers. For combined reader
values as repeated measurements (or responses)and obesity (Additional file 1: Table S2) or to perform
analyses on subgroups of solid and cystic lesions
(Additional file 1: Table S3). Such analyses were consid-
ered exploratory and are presented in Additional file 1: Ta-
bles S2 and S3.
Accuracy in patients with chronic kidney disease for small
(<3 cm) vs. large (≥3 cm) lesions
Accuracy was examined for lesions <3 cm (n = 23) and
≥3 cm (n = 21) in diameter in patients with and without
CKD. More patients with CKD had smaller lesions (16/23)
than larger lesions (9/21). For smaller lesions, when com-
bining results from both readers, overall accuracy de-
creased from 71% (95% CI: 33%, 93%) for patients with no
CKD to 56% (95% CI: 34%, 76%) for patients with CKD.analysis) and tissue diagnosis or follow-up imaging diagnosis
Reader 2 Combined readers
iagnosis Tissue or follow-up
imaging
(N = 44)
Tissue
diagnosis
(N = 23)
Tissue or follow-up
imaging
(N = 44)
%
100%)
21]
100%
(100%, 100%)
[22/22]
95%
(83%, 99%)
96%
(84%, 99%)
0%)
2]
41%
(20%, 61%)
[9/22]
0%
(0%, 0%)
50%
(32%, 68%)
%
00%)
23]
70%
(57%, 84%)
[31/44]
87%
(69%, 95%)
73%
(59%, 83%)
l reads]. CEUS images were read by 2 independent readers. Results were
result, generalized estimating equations were used considering two readers’
Fig. 2 Inter-reader agreement. The rate of agreement between the two readers was calculated for each individual lesion characteristic, the Bosniak class
designation (or solid designation) and the overall designation of malignant or benign based on Bosniak class (Bosniak I, II and IIF considered benign and
Bosniak III, IV and solid considered malignant)
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readers, overall accuracy decreased from 96% (95% CI:
76%, 99%) for patients with no CKD to 72% (95% CI: 46%,
89%) for patients with CKD. There was no difference in
sensitivity for larger lesions but a decrease in sensitivity
from 100% (95% CI: 100%, 100%) to 75% (95% CI: 32%,
95%) was obersved in smaller lesions. Results are pre-
sented in Additional file 1: Table S4.
Discussion
Evaluation of kidney lesions by ultrasound has historic-
ally been limited by lack of enhancement. Contrast-
enhanced CT/MR has been the imaging standard. How-
ever, iodinated contrast agents may worsen kidney func-
tion, and gadolinium agents may cause nephrogenicTable 3 Agreement between contrast CT/MR and CEUS diagnosisa
Reader 1 Reader 2
CT/MR+ CEUS+ 89%
(76%, 100%)
[17/19]
96%
(87%, 100%)
[23/24]
CEUS- 11%
(0%, 24%)
[2/19]
4%
(0%, 13%)
[1/24]
CT/MR- CEUS+ 83%
(54%, 100%)
[5/6]
100%
(100%, 100%)
[1/1]
CEUS- 17%
(0%, 46%)
[1/6]
0%
(0%, 0%)
[0/1]
Overall Agreement 72%
(54%, 90%)
[18/25]
92%
(81%, 100%)
[23/25]
aResults presented as rate of agreement with (95% CI) and [CEUS interpretation/
CT or MR interpretation]systemic fibrosis in patients with advanced CKD. The
primary goal of this pilot study was to explore the detec-
tion of microbubble contrast in kidney lesions among
patients with and without CKD and to test the accuracy
of CEUS for characterizing these lesions as malignant or
benign (Fig. 3). We found that the sensitivity of CEUS,
whether compared to tissue diagnosis or follow-up im-
aging, is high and comparable to the reported sensitivities
of CT (83–100%) and MR (81–100%) [21–24, 40] among
patients with and without CKD. High sensitivity provides
high certainty that a negative test in an individual means
the individual does not have the disease, essentially ruling
out malignancy.
Although we found high sensitivity with CEUS, specifi-
city was low. Whether compared to tissue diagnosis or
tissue diagnosis/follow-up imaging, specificity of CEUS
is lower than reported CT (51–96%) and MR (71–100%)
specificities [21–24, 40]. Low specificity means a large
number of false positives, thus a positive test does not
mean the individual has the disease and cannot rule in
malignancy very well.
A test with high sensitivity and lower specificity (for
example, mammography or CT for lung cancer) is suit-
able for screening purposes. Benign cystic masses are
common in renal insufficiency and distinguishing malig-
nant from benign cysts is a diagnostic challenge. CT or
MR is the current standard, but performing CT/MR on
all patients with cystic masses would be prohibitively
costly and expose a large number of patients to radiation
or potentially nephrotoxic contrast agents. CEUS’s ability
to exclude malignancy with minimal risk of adverse
effects means that the use of CT/MR could be narrowed
down to only those patients with a positive CEUS.
Table 4 Accuracy of CEUS based on severity of CKD compared to the secondary reference standarda
Reader 1 Reader 2 Combined readers
Early CKD
(eGFR ≥30 mL/min)
(N = 11)
Advanced CKD
(eGFR <30 mL/min)
(N = 14)
Early CKD
(eGFR ≥30 mL/min)
(N = 11)
Advanced CKD
(eGFR <30 mL/min)
(N = 14)
Early CKD
(eGFR ≥30 mL/min)
(N = 11)
Advanced CKD
(eGFR <30 mL/min)
(N = 14)
Sensitivity 100%
(100%, 100%)
[2/2]
67%
(13%, 100%)
[2/3]
100%
(100%, 100%)
[2/2]
100%
(100%, 100%)
[3/3]
100%
(100%, 100%)
83%
(42%, 97%)
Specificity 78%
(20%, 100%)
[7/9]
55%
(25%, 84%)
[6/11]
67%
(36%, 97%)
[6/9]
27%
(1%, 54%)
[3/11]
72%
(40%, 91%)
41%
(20%, 66%)
Overall Accuracy
(no. correct/total)
82%
(59%, 100%)
[9/11]
57%
(31%, 83%)
[8/14]
73%
(46%, 99%)
[8/11]
43%
(17%, 69%)
[6/14]
77%
(48%, 93%)
50%
(29%, 71%)
aResults presented as accuracy metrics (95% CI) and [positive or negative reads/total reads]. CEUS images were read by 2 independent readers. Results were
considered per reader and as a combination of the 2 readers. For combined reader result, generalized estimating equations were used considering two readers’
values as repeated measurements (or responses)
Abbreviations: CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate
Chang et al. BMC Nephrology  (2017) 18:266 Page 9 of 13In the subgroup of patients who also had CT/MR, the
number of patients who were CEUS negative but CT/
MR positive is smaller than the CEUS positive but CT/
MR negative group, suggesting that CEUS tends to as-
sign a higher Bosniak category (or solid designation)
than CT/MR (Fig. 4 and Fig. 5). This analysis does not
take diagnosis into account and can therefore only be
used to suggest that CEUS is more likely to call a lesion
malignant than CT/MR and does not lead to conclu-
sions about false positive or negative rates.
There are three possible explanations: First, ultrasound
is more sensitive than CT/MR for detecting the presence
of intravascular contrast. Unlike CT and MR agents,
microbubble contrast agents remain intravascular: they
are not filtered by glomeruli and do not extravasate into
the interstitial space [41]. This may lead to more prom-
inent internal enhancement with CEUS than CT/MR
agents [22, 23]. Second, ultrasound has greater spatial
resolution than CT/MR: in some cases (Fig. 4), cysts that
appear simple on CT/MR show internal features on
ultrasound, including septations not seen on CT,Fig. 3 Complex cystic lesions in 2 patients with chronic kidney disease of d
cystic lesions, called Bosniak IV by both readers (long arrows). Mural nodularit
RCC on pathology. However, the 72-year old woman in 3a had early kidney d
case demonstrates homogeneous enhancement. 3b is a case of a 67-y
kidney parenchyma appears very different, demonstrating reduced, patcresulting in a higher Bosniak grade using definitions
based on CT or MR imaging. Better spatial and contrast
resolution is an important advantage to examining le-
sions with CEUS; however, to reduce the false positive
rate, the grading system will need to be modified to take
this into account. Future, larger studies should be per-
formed to develop a revised classification system [42].
Using objective measures of enhancement, similar to
Hounsfield units for CT, may also improve CEUS accur-
acy. Furthermore, new CEUS imaging techniques such as
super-resolution imaging [43], molecular imaging [44],
and acoustic angiography [45] may further improve speci-
ficity to malignant lesions as they are translated into the
clinic. The third possibility is that relative inexperience
with CEUS compared to CT or MR leads to upstaging of
kidney lesions.
Few studies have looked specifically at the use of CEUS
for characterizing lesions in patients with CKD [46]. In
this study, we examined patients with and without CKD.
With more advanced CKD, overall accuracy declined, due
largely to a decrease in specificity. While sensitivity onlyifferent severity. Sagittal CEUS images of two patients with complex
y (dashed arrows) is present in both cysts. Both lesions were confirmed as
isease, and the non-neoplastic kidney parenchyma (short arrow) in this
ear old man with advanced kidney disease on dialysis in which the
hy enhancement (short arrow)
Fig. 4 Upstaging of cystic lesion on contrast-enhanced CT and CEUS due to greater special resolution. Contrast enhanced CT (4a) showing a
smaller hyperdense cyst (long arrow) classified by readers as Bosniak II by one reader and IIF by the other in a 75 year old man. Adjacent to this
is a large simple cyst (Bosniak I) (short arrow). On CEUS (4b), the smaller cyst (long arrow) shows enhancing internal septa and a solid component
invisible on the CT that resulted in a Bosniak III classification. The larger cyst (short arrow) demonstrates internal features such as septations and
wall irregularity that were also not visible on the CT. This illustrates the greater spatial resolution of CEUS compared to CT, and may explain why
applying the Bosniak criteria to CEUS leads to upstaging
Chang et al. BMC Nephrology  (2017) 18:266 Page 10 of 13dropped from 100% for early CKD to 83% for advanced
CKD, specificity dropped from 72% to 41%. The reason
for this requires further investigation, but we observed
that while we were able to detect contrast enhancement in
the uninvolved parenchyma for all patients, parenchymal
enhancement was more heterogeneous and reduced in
patients with CKD compared to non-CKD patients. We
therefore hypothesize that a decrease in background
parenchymal enhancement accentuates the difference in
lesion enhancement compared to surrounding paren-
chyma. This abnormal parenchymal enhancement is even
further pronounced in advanced CKD and may cause the
lesion to stand out more, creating the perception that it is
enhancing. This would be expected to primarily affect
specificity, as the false-positive rate would increase with
worsening CKD. With this in mind, we hypothesized that
subjects with vascular CKD pathology (diabetes or hyper-
tension) would have more false positives than non-
vascular etiologies (cystic, glomerular, drug-related) butFig. 5 Upstaging of cystic lesion on contrast-enhanced CT and CEUS due to
patient with advanced kidney disease and kidney transplant, wall thickening i
measurements were seen pre- (5a, 35HU) and post-contrast (5b, 37.5 HU). Thi
CEUS (5c), the thickened wall is irregular and clearly enhances. Both readers re
illustrates that CEUS has greater contrast resolution than CT, and may explainfound no significant differences, likely due to small num-
bers. This should be explored further in larger popula-
tions. Nonetheless, the high sensitivity for ruling out
malignancy in the CKD population suggests that this
modality could be used for screening following non-
contrast ultrasound or CT for patients in whom contrast-
enhanced CT/MR is contraindicated (Fig. 6). Larger studies
are needed to confirm and extend our findings.
Based on our findings, we suggest that CEUS be con-
sidered to evaluate low to moderate-risk lesions in
patients who have absolute or relative contra-indications
to contrast CT or MR. If CEUS does not detect lesion
enhancement, the patient may not need to undergo con-
trast CT or MR. If CEUS does detect lesion enhance-
ment, further imaging should be considered. In addition,
CEUS may have an application as a secondary test for
lesions not definitively diagnosed by either contrast CT
or MR. Due to the greater sensitivity to enhancement
and special resolution, CEUS may be able to detectgreater contrast resolution. On the contrast-enhanced CT of a 44-year old
s present (arrow). ROI shows no enhancement: the same Hounsfield unit
s was read by one radiologist as Bosniak II and the other as Bosniak III. On
ad the lesion (circled) one stage higher as Bosniak III and IV on CEUS. This
why applying the Bosniak criteria to CEUS leads to upstaging
Fig. 6 Partly cystic lesion on CEUS compared to gray scale ultrasound. Gray scale longitudinal ultrasound (6a) shows an apparently partly cystic
lesion within a strongly echogenic kidney in a 53-year old man with advanced CKD and hence contraindications to both contrast CT and MR. The
lesion demonstrates intense homogeneous enhancement on CEUS (6b) and is larger but otherwise unchanged on 21-month follow-up imaging.
It appeared partly cystic on grayscale ultrasound because it was surrounded by strongly echogenic CKD tissue. This case illustrates the difficulty of
differentiating tumors from benign cysts on conventional ultrasound in the setting of advanced CKD
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This potential application should be evaluated in future
studies.
Although CEUS is not yet FDA-approved for kidney im-
aging in the United States, it is increasingly used off label.
Interpretation tools, such as the customized GUI, that ad-
dress each component lesion characteristic of the Bosniak
classification system, can assess reader consistency and
inter-reader agreement. Observational training visits to in-
stitutions that have experience and familiarity with CEUS
will improve implementation and interpretation accuracy.
This study has limitations. First, this is a pilot study
with a relative small size population from a single center.
Due to the small size, meaningful subgroup analyses,
such as those at each stage of CKD and those with cystic
vs. solid lesions, was not possible. Because of this limita-
tion, the conclusions drawn are preliminary in nature
and should be interpreted with caution. Future, larger,
multicenter studies are needed to determine the true
accuracy of CEUS among individuals with diverse stages
of CKD. Second, the blinded readers in this study were
academic genitourinary radiologists with fellowship
training in ultrasound. They underwent a preliminary
training session and performed CEUS literature review,
but neither had prior experience with CEUS. However,
their background is not atypical as physicians are now
becoming more familiar with CEUS in the United States,
particularly in academic centers. Reassuringly, the sensi-
tivities observed were similar to those reported by more
experienced centers [34]. As there is little available for-
mal training, development of a training program and
experience with interpretation of CEUS is needed before
widespread implementation. Additionally, because CEUS
is a perfusion study, applying objective perfusion param-
eters could increase accuracy. Third, the referencestandard of tissue diagnosis was not available for all
patients because many indeterminate lesions underwent
imaging surveillance rather than biopsy or surgery. A
minimum of one-year follow-up was accepted, but the
ideal follow-up period is 3–5 years, depending on lesion
complexity, as some renal cancers are slow growing.
Until longer follow-up data on more patients is obtained,
malignancy cannot be ruled out with a Bosniak IIF
lesion, and these patients would still need to be followed,
as is the case with contrast CT and MR. Fourth, both
cystic and solid lesions were included. In order to more
accurately determine accuracy and potential modifica-
tions to Bosniak criteria for CEUS in a CKD population,
future studies will need to include primarily cystic
lesions. Fifth, the referral source for the two groups,
non-CKD and CKD, was different. This introduces po-
tential bias since the non-CKD group came primarily
from urology clinic where patients were referred for
evaluation of highly suspicious lesions (i.e. likely higher
risk lesions), and the CKD group came primarily from
non-urologists who were longitudinally following inde-
terminate lesions (i.e. likely lower risk lesions). Lastly, as
with any ultrasound study, obesity, lesion location and
motion artifact from breathing are technical limitations.
Conclusion
The traditional Bosniak classification system was de-
veloped to classify kidney cystic lesions based on
contrast-enhanced CT characteristics We adapted this
classification system for B-mode US/CEUS and found
that it has potential as a test to exclude malignancy
based on a sensitivity comparable to CT/MRI, but it
does not yet have good specificity. Low specificity
might be attributed to the greater spatial resolution
and contrast detection with CEUS compared to
Chang et al. BMC Nephrology  (2017) 18:266 Page 12 of 13contrast-enhanced CT, leading to upstaging of lesions.
It may also be attributed to lack of experience inter-
preting CEUS studies. Our results suggest that with
further refinement of a classification system and more
training, CEUS may be an alternative to contrast CT or
MR for characterizing indeterminate kidney lesions, par-
ticularly in patients with CKD or other contraindications
to contrast CT or MR. However, if the traditional Bosniak
criteria are used for CEUS, malignancy can still be ex-
cluded but a positive CEUS result will require further
diagnostic evaluation due to its low specificity. Improved
specificity may be accomplished with training programs
for radiologists and revisions to the Bosniak criteria,
potentially adopting a classification scheme proposed by
Barr et al. [24] which incorporates both solid and cystic le-
sions. Larger studies focused on cystic lesions, particularly
in patients with later stages of CKD are needed to confirm
and extend our findings and inform classification criteria
revisions.
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